Delving into the Latest Updates on Neostigmine Bromide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Neostigmine bromide (JAN/USP/INN), NSC-757233, Prostigmin

+ [2]

Target

ACHE

Action

inhibitors, antagonists

Mechanism

AChE inhibitors(Acetylcholinesterase inhibitors), Muscle relaxation antagonists

Therapeutic Areas

NeoplasmsImmune System DiseasesNervous System Diseases+ [2]

Active Indication

Chronic gastritisConstipation - functionalDysuria+ [1]

Inactive Indication-

Originator Organization-

Active Organization

Kyowa Pharmaceutical Industry Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (14 Apr 1956),

Chronic gastritisConstipation - functionalDysuria+ [1]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC12H19BrN2O2

InChIKeyLULNWZDBKTWDGK-UHFFFAOYSA-M

CAS Registry114-80-7

Lower abdominal surgeries often result in severe pain, which in turn can cause rapid and shallow breathing, retention of secretions and poor patient compliance. Justifiably, apart from the fear for the surgery outcome, patients are concerned mainly with postoperative pain. If treated inadequately, acute pain can have serious consequences for patient health mainly with postoperative complications, prolonged recovery and increased length of hospital stay. Higher levels of postoperative pain and pain distress are associated with increased morbidity, poorer functional recovery, and reduced quality of life.
Aim of the study To compare the duration, quality of analgesia, and side effects between intrathecal Magnesium sulfate, neostigmine and fentanyl as adjuvant for bubivacaine as postoperative analgesia in lower abdominal surgeries

Start Date01 Dec 2024

Sponsor / Collaborator

Assiut University

CTRI/2023/07/055054

/ Not yet recruitingPhase 4IIT

Effect of neostigmine on attenuation of proinflammatory cytokines secretion when given as an adjunctive therapy in septic shock: A Randomized controlled trial - NIL

Start Date20 Jul 2023

Sponsor / Collaborator

All India Institute of Medical Sciences

PACTR202304565008785

/ RecruitingNot ApplicableIIT

Intramuscular Neostigmine and Postoperative Urinary Retention After Spinal Anesthesia for knee Arthroscopy, a Prospective Randomized Controlled Study

Start Date15 Apr 2023

Sponsor / Collaborator

Mansoura University

100 Clinical Results associated with Neostigmine Bromide

Login to view more data

100 Translational Medicine associated with Neostigmine Bromide

Login to view more data

100 Patents (Medical) associated with Neostigmine Bromide

Login to view more data

3,748

Literatures (Medical) associated with Neostigmine Bromide

01 May 2025·DYES AND PIGMENTS

Rational design of fast-responding and highly selective fluorescent probes for detecting and imaging acetylcholinesterase homeostatic changes in Alzheimer's disease

Author: Ullah, Inam ; Shao, Yiwen ; Shen, Jiawen ; Zhang, Chenrun ; Zhu, Hai-Liang

Alzheimer′s disease (AD) is a progressive amnestic cognitive deteriorating neurodegenerative disease.Acetylcholinesterase (AChE) has a very high catalytic hydrolysis efficiency, which can rapidly hydrolyze acetylcholine into choline, playing a critical role in regulating the nervous system.Therefore, we designed and synthesized a fluorescent probe capable of quant. detecting AChE called ACP.Most strikingly, an extremely low detection limit of 0.341U/mL is far superior to those of many probes.The approach of utilizing ACP enabled us to swiftly identify and track real-time alterations in intracellular AChE levels.Addnl., our study marks the pioneering use of ACP in effectively detecting an increase in AChE expression in C. elegans and mice models of Alzheimer′s disease (AD).In conclusion, this study provides a new tool for quant. detecting AChE levels and shows great potential for application in AChE-related studies.

01 Mar 2025·OBESITY SURGERY

Effect of Sugammadex on Post-operative Urinary Retention After Bariatric Surgery

Article

Author: Rosenbluth, Amy ; Spaniolas, Konstantinos ; Smolkin, Caroline ; Crosby, Patrick ; Swaszek, Luke ; Sanicola, Caroline ; Fuller, Samantha ; Pryor, Aurora

BACKGROUND:

The incidence of post operative urinary retention (POUR) after bariatric surgery has been described to be anywhere between 5 and 8%. This incidence is thought to be related in part to medications for neuromuscular blockade (NMBA) reversal. The purpose of this study was to determine the difference between sugammadex and neostigmine with an antimuscarinic agent on reducing POUR in bariatric patients.

METHODS:

Single center, retrospective, cohort, chart review study performed at a single academic institution. Patients who underwent primary laparoscopic sleeve gastrectomy (LSG) or laparoscopic Roux-en-Y gastric bypass (LGBP) and were administered NMBAs, with subsequent reversal with either neostigmine with an antimuscarinic agent (N = 121) or with sugammadex (N = 107), formed the cohort. POUR was defined as the inability to void post-operatively within 6 h, requiring eventual urinary straight catheterization or placement of an indwelling urinary catheter at any time before discharge.

RESULTS:

A total of 7.9% developed POUR following bariatric surgery. The incidence of POUR was significantly lower in the sugammadex group when compared to the neostigmine group (1.9% vs 13.2%, p < 0.001). The length of stay was also significantly shorter in the sugammadex group when compared to the neostigmine group (1.7 (SD 0.7) vs 1.9 days (SD 0.6), p < 0.001). There was no significant difference in the rate of readmission (4.1% vs 3.7%, p = 0.561) or emergency department visits (10.7% vs 10.3%, p = 0.564). Multivariable regression demonstrated that sugammadex use was independently associated with a lower likelihood of developing POUR after surgery (OR 0.127 (95% CI 0.028-0.586), p = 0.008).

CONCLUSION:

The rate of POUR after bariatric surgery was significantly lower in the patients undergoing NMBA reversal with sugammadex when compared to neostigmine. This group also experienced a shorter length of stay.

01 Mar 2025·Journal of Evidence Based Medicine

Pharmacological Interventions for Acute Pancreatitis in Adults: An Overview of Systematic Reviews

Review

Author: Sun, Xin ; He, Qiao ; Ding, Ling ; Sun, Che ; Wang, Wen ; Jian, Linge ; Xu, Jiayue ; Wang, Yuning

ABSTRACT:

Aim:

To provide a comprehensive assessment of the efficacy and safety of pharmacological interventions for AP.

Methods:

This was an overview of systematic reviews based on randomized controlled trials comparing pharmacological interventions with placebo or blank control in adults with AP. We searched PubMed, Embase, and the Cochrane Database of Systematic Reviews from inception to January 13, 2024, with an update on February 4, 2025. The effect value of each medication on each outcome of interest defined as a “combo” was assessed. Findings were categorized as efficacious, not efficacious, or inconclusive.

Results:

Fifteen reviews (167 unique trials, 12,930 participants) reported the efficacy of 14 medications on 5 outcomes, yielding 35 distinct combos. Seven combos showed efficacy with low certainty evidence: low molecular weight heparin (risk ratio 0.31, 95% confidence interval, 0.18–0.51), omega‐3 fatty acids (0.30, 0.14–0.65), and antioxidants (0.69, 0.49–0.98) for mortality; low molecular weight heparin (0.38, 0.22–0.65), chengqi‐series decoctions (0.48, 0.36–0.63), and ulinastatin (0.43, 0.24–0.78) for multiple organ failure; and neostigmine (mean difference –2.81, 95 % confidence interval –3.75 to –1.87) for length of intensive care unit stay. Half of the remaining combos showed no efficacy, while the other half was inconclusive for very low certainty evidence. Safety data were limited, with one review reporting no significant adverse events for neostigmine.

Conclusions:

Some pharmacological interventions exhibited potential efficacy for specific AP outcomes, albeit with low certainty evidence. Further verifying those medications is crucial in advancing the treatment landscape for AP.

100 Deals associated with Neostigmine Bromide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00995	Neostigmine Bromide	S01EB06 N07AA01	DBSALT001191

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Chronic gastritis	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	14 Apr 1956
Constipation - functional	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	14 Apr 1956
Dysuria	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	14 Apr 1956
Myasthenia Gravis	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	14 Apr 1956

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02909439 (CTgov)	Phase 4	Reversal of Neuromuscular Blockade	80	Neostigmine (Neostigmine)	vvhngidagy(xwezgwigva) = aehhxkuewc kyqpalgenq (wxndhmakyc, jrosflkhrh - rqrzhhfvco) View more	-	22 May 2020
				Sugammadex (Sugammadex)	vvhngidagy(xwezgwigva) = dwqxvgkbft kyqpalgenq (wxndhmakyc, uajlrvzxja - jzyrjdpntv) View more
NCT01962298 (SUDIA, CTgov)	Phase 3	Respiratory Diseases \| Muscle fatigue \| Muscle Weakness	75	placebo+Single rocuronium dose (Single Rocuronium Dose - Placebo)	cyvgsvyioz(lgdkojbnlf) = hdftbjyslt zceeulrmfq (pcazmsijzs, pzhxaltzok - brlhlkvnhj) View more	-	24 Oct 2018
				sugammadex 2mg/kg+Single rocuronium dose (Single Rocuronium Dose - Sugammadex)	cyvgsvyioz(lgdkojbnlf) = khggydhaoz zceeulrmfq (pcazmsijzs, nlggbivbno - czhgpeotft) View more